On the public citation graph

Heterogeneity of Response and Immune System Activity during Treatment with Nivolumab in Hepatocellular Carcinoma: Results from a Single-Institution Retrospective Analysis

https://doi.org/10.3390/cancers13020213

0 signed · 69 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.

Claim with ORCID

Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.

See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jamaoncol.2020.4564openalex-snapshot

Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib

inferredcites →https://doi.org/10.1002/hep.25777openalex-snapshot

Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma

inferredcites →https://doi.org/10.1002/hep.26731openalex-snapshot

Immunodominance and functional alterations of tumor-associated antigen-specific CD8+ T-cell responses in hepatocellular carcinoma

inferredcites →https://doi.org/10.1002/hep4.1132openalex-snapshot

Distinct clinical and magnetic resonance features of metastatic hepatocellular carcinoma treated with pembrolizumab: A case report of late response after pseudoprogression

inferredcites →https://doi.org/10.1007/s00262-013-1447-1openalex-snapshot

Increase in CD14+HLA-DR−/low myeloid-derived suppressor cells in hepatocellular carcinoma patients and its impact on prognosis

inferredcites →https://doi.org/10.1007/s00262-015-1768-3openalex-snapshot

Metastatic spread in patients with non-small cell lung cancer is associated with a reduced density of tumor-infiltrating T cells

inferredcites →https://doi.org/10.1007/s00262-018-2255-4openalex-snapshot

Opposing roles of eosinophils in cancer

inferredcites →https://doi.org/10.1007/s11523-020-00757-3openalex-snapshot

Prognostic Role of Blood Eosinophil Count in Patients with Sorafenib-Treated Hepatocellular Carcinoma

inferredcites →https://doi.org/10.1016/j.cell.2017.07.025openalex-snapshot

Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient

inferredcites →https://doi.org/10.1016/j.ejca.2017.10.017openalex-snapshot

Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria

inferredcites →https://doi.org/10.1016/j.jaut.2009.08.008openalex-snapshot

Immune tolerance: What is unique about the liver

inferredcites →https://doi.org/10.1016/j.jcmgh.2019.08.004openalex-snapshot

Unique T-Cell Populations Define Immune-Inflamed Hepatocellular Carcinoma

inferredcites →https://doi.org/10.1016/j.jhep.2019.09.026openalex-snapshot

mRECIST for HCC: Performance and novel refinements

inferredcites →https://doi.org/10.1016/j.jhep.2020.08.010openalex-snapshot

Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma

inferredcites →https://doi.org/10.1016/j.jtho.2017.04.027openalex-snapshot

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab

inferredcites →https://doi.org/10.1016/s0140-6736(16)32453-9openalex-snapshot

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

inferredcites →https://doi.org/10.1016/s0140-6736(17)31046-2openalex-snapshot

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial

inferredcites →https://doi.org/10.1016/s0140-6736(18)30207-1openalex-snapshot

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

inferredcites →https://doi.org/10.1016/s1470-2045(15)00050-9openalex-snapshot

Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial

inferredcites →https://doi.org/10.1016/s1470-2045(17)30074-8openalex-snapshot

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

inferredcites →https://doi.org/10.1016/s1470-2045(18)30351-6openalex-snapshot

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

inferredcites →https://doi.org/10.1016/s1470-2045(18)30937-9openalex-snapshot

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

inferredcites →https://doi.org/10.1038/bjc.2012.581openalex-snapshot

Cancer heterogeneity: implications for targeted therapeutics

inferredcites →https://doi.org/10.1038/bjc.2016.308openalex-snapshot

Patterns of response to anti-PD-1 treatment: an exploratory comparison of four radiological response criteria and associations with overall survival in metastatic melanoma patients

inferredcites →https://doi.org/10.1038/ni.2035openalex-snapshot

T cell exhaustion

inferredcites →https://doi.org/10.1038/nrgastro.2015.173openalex-snapshot

Immunological landscape and immunotherapy of hepatocellular carcinoma

inferredcites →https://doi.org/10.1038/s41422-020-0337-2openalex-snapshot

The future of cancer immunotherapy: microenvironment-targeting combinations

inferredcites →https://doi.org/10.1038/s41598-020-60437-0openalex-snapshot

Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics

inferredcites →https://doi.org/10.1038/s41598-020-71340-zopenalex-snapshot

Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients

inferredcites →https://doi.org/10.1038/srep13886openalex-snapshot

Non-Classical monocytes display inflammatory features: Validation in Sepsis and Systemic Lupus Erythematous

inferredcites →https://doi.org/10.1038/srep14757openalex-snapshot

Identification of a FOXP3+CD3+CD56+ population with immunosuppressive function in cancer tissues of human hepatocellular carcinoma

inferredcites →https://doi.org/10.1053/j.gastro.2008.03.020openalex-snapshot

A New Population of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma Patients Induces CD4+CD25+Foxp3+ T Cells

inferredcites →https://doi.org/10.1053/j.gastro.2016.02.040openalex-snapshot

Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib

inferredcites →https://doi.org/10.1056/nejmoa0708857openalex-snapshot

Sorafenib in Advanced Hepatocellular Carcinoma

inferredcites →https://doi.org/10.1056/nejmoa1717002openalex-snapshot

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

inferredcites →https://doi.org/10.1056/nejmoa1915745openalex-snapshot

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

inferredcites →https://doi.org/10.1056/nejmra1713263openalex-snapshot

Hepatocellular Carcinoma

inferredcites →https://doi.org/10.1080/2162402x.2016.1214788openalex-snapshot

Activity and safety of radiotherapy with anti-PD-1 drug therapy in patients with metastatic melanoma

inferredcites →https://doi.org/10.1093/annonc/mdz003openalex-snapshot

Novel patterns of response under immunotherapy

inferredcites →https://doi.org/10.1111/cas.14706openalex-snapshot

Eosinophil prognostic scores for patients with head and neck squamous cell carcinoma treated with nivolumab

inferredcites →https://doi.org/10.1126/science.aac9407openalex-snapshot

Patrolling monocytes control tumor metastasis to the lung

inferredcites →https://doi.org/10.1136/jitc-2020-001033openalex-snapshot

Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study

inferredcites →https://doi.org/10.1158/1078-0432.ccr-17-2386openalex-snapshot

Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab

inferredcites →https://doi.org/10.1158/2326-6066.cir-16-0325openalex-snapshot

Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC

inferredcites →https://doi.org/10.1159/000489021openalex-snapshot

Increased Expression of Programmed Death-Ligand 1 in Infiltrating Immune Cells in Hepatocellular Carcinoma Tissues after Sorafenib Treatment

inferredcites →https://doi.org/10.1159/000501275openalex-snapshot

Differential Organ-Specific Tumor Response to Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

inferredcites →https://doi.org/10.1159/000502714openalex-snapshot

Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience

inferredcites →https://doi.org/10.1186/s40425-016-0117-1openalex-snapshot

Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study

inferredcites →https://doi.org/10.1186/s40425-019-0749-zopenalex-snapshot

Immunotherapy in hepatocellular carcinoma: the complex interface between inflammation, fibrosis, and the immune response

inferredcites →https://doi.org/10.1186/s41747-019-0134-1openalex-snapshot

Imaging of tumour response to immunotherapy

inferredcites →https://doi.org/10.1200/jco.20.00808openalex-snapshot

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

inferredcites →https://doi.org/10.18632/oncotarget.11565openalex-snapshot

Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib

inferredcites →https://doi.org/10.18632/oncotarget.4572openalex-snapshot

Characterization of tumor infiltrating lymphocytes in paired primary and metastatic renal cell carcinoma specimens

inferredcites →https://doi.org/10.2217/imt-2020-0265openalex-snapshot

Prognosticating Role of Serum Eosinophils on Immunotherapy Efficacy in Patients with Advanced Melanoma

inferredcites →https://doi.org/10.3322/caac.21492openalex-snapshot

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

inferredcites →https://doi.org/10.3389/fimmu.2018.00367openalex-snapshot

The Role of Natural Killer T Cells in Cancer—A Phenotypical and Functional Approach

inferredcites →https://doi.org/10.3390/cancers12051089openalex-snapshot

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

inferredcites →https://doi.org/10.4049/jimmunol.182.1.240openalex-snapshot

Cancer-Expanded Myeloid-Derived Suppressor Cells Induce Anergy of NK Cells through Membrane-Bound TGF-β1

inferredcites →https://doi.org/10.7326/0003-4819-87-5-642_1openalex-snapshot

Hepatocellular Carcinoma.

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4775796openalex-extracted

Monocyte-Related Markers as Predictors of Immune Checkpoint Inhibitor Efficacy and Immune-Related Adverse Events: A Systematic Review and Meta-Analysis

inferred← citeshttps://doi.org/10.1002/cpt.70336openalex-snapshot

Model‐Informed Dosing Strategies for Epcoritamab Monotherapy in Relapsed or Refractory Large B‐Cell Lymphoma

inferred← citeshttps://doi.org/10.1007/s00432-022-04512-1openalex-snapshot

Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

inferred← citeshttps://doi.org/10.1007/s10555-025-10246-6openalex-snapshot

Monocyte-related markers as predictors of immune checkpoint inhibitor efficacy and immune-related adverse events: a systematic review and meta-analysis

inferred← citeshttps://doi.org/10.1007/s40278-021-92489-3openalex-snapshot

Nivolumab

inferred← citeshttps://doi.org/10.1055/s-0043-1776127openalex-snapshot

Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma

inferred← citeshttps://doi.org/10.1097/rlu.0000000000005896openalex-snapshot

Prognostic Significance of Volumetric Parameters on Pretreatment FDG PET/CT in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab Therapy

inferred← citeshttps://doi.org/10.1159/000525582openalex-snapshot

Systemic Treatment of Advanced Unresectable Hepatocellular Carcinoma after First-Line Therapy: Expert Recommendations from Hong Kong, Singapore, and Taiwan

inferred← citeshttps://doi.org/10.1177/03008916211033353openalex-snapshot

Efficacy of lenvatinib plus pembrolizumab in hepatocellular carcinoma with metachronous lung metastasis: a report of two cases

inferred← citeshttps://doi.org/10.2147/jhc.s358082openalex-snapshot

Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook

Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.